Literature DB >> 15981472

Recombinant rhabdoviruses: vectors for vaccine development and gene therapy.

S Finke1, K K Conzelmann.   

Abstract

The establishment of methods to recover rhabdoviruses from cDNA, so-called reverse genetics systems, has made it possible to genetically engineer rhabdoviruses and to study all aspects of the virus life cycle by introducing defined mutations into the viral genomes. It has also opened the way to make use of the viruses in biomedical applications such as vaccination, gene therapy, or oncolytic virotherapy. The typical gene expression mode of rhabdoviruses, a high genetic stability, and the propensity to tolerate changes in the virus envelope have made rhabdoviruses attractive, targetable gene expression vectors. This chapter provides an overview on the possibilities to manipulate biological properties of the rhabdoviruses that may be important for further development of vaccine vectors and examples of recombinant rhabdoviruses expressing foreign genes and antigens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15981472     DOI: 10.1007/3-540-27485-5_8

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  15 in total

1.  Highly efficient DNA-free plant genome editing using virally delivered CRISPR-Cas9.

Authors:  Xiaonan Ma; Xiaoyan Zhang; Huimin Liu; Zhenghe Li
Journal:  Nat Plants       Date:  2020-06-29       Impact factor: 15.793

2.  Reverse genetics of rabies virus: new strategies to attenuate virus virulence for vaccine development.

Authors:  Shimao Zhu; Hui Li; Chunhua Wang; Farui Luo; Caiping Guo
Journal:  J Neurovirol       Date:  2015-05-21       Impact factor: 2.643

3.  Effect of time delays in an HIV virotherapy model with nonlinear incidence.

Authors:  Yun Tian; Yuan Yuan
Journal:  Proc Math Phys Eng Sci       Date:  2016-02       Impact factor: 2.704

Review 4.  Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.

Authors:  Eric Hastie; Valery Z Grdzelishvili
Journal:  J Gen Virol       Date:  2012-10-10       Impact factor: 3.891

5.  Attenuation of rabies virus replication and virulence by picornavirus internal ribosome entry site elements.

Authors:  Adriane Marschalek; Stefan Finke; Martin Schwemmle; Daniel Mayer; Bernd Heimrich; Lothar Stitz; Karl-Klaus Conzelmann
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

6.  Identification of sendai virus L protein amino acid residues affecting viral mRNA cap methylation.

Authors:  Andrea M Murphy; Valery Z Grdzelishvili
Journal:  J Virol       Date:  2008-12-03       Impact factor: 5.103

7.  Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression.

Authors:  Susan E Witko; J Erik Johnson; Narender K Kalyan; Barbara K Felber; George N Pavlakis; Maninder K Sidhu; R Michael Hendry; Stephen A Udem; Christopher L Parks
Journal:  J Virol Methods       Date:  2009-11-24       Impact factor: 2.014

8.  Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques.

Authors:  R Xu; F Nasar; S Megati; A Luckay; M Lee; S A Udem; J H Eldridge; M A Egan; E Emini; D K Clarke
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

9.  Double-labeled rabies virus: live tracking of enveloped virus transport.

Authors:  Yvonne Klingen; Karl-Klaus Conzelmann; Stefan Finke
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

10.  Type III interferon attenuates a vesicular stomatitis virus-based vaccine vector.

Authors:  Ryann C Guayasamin; Tracy D Reynolds; Xin Wei; Mai Fujiwara; Michael D Robek
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.